UPDATE: Truist Securities Starts Veracyte, Inc (VCYT) at Buy, "Long runway to further penetrate the market'

January 27, 2021 4:13 PM EST
Get Alerts VCYT Hot Sheet
Price: $53.57 -2.67%

Rating Summary:
    10 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 8 | New: 31
Trade Now! 
Join SI Premium – FREE
(Updated - January 28, 2021 9:07 AM EST)

Truist Securities analyst Sandy Draper initiates coverage on Veracyte, Inc (NASDAQ: VCYT) with a Buy rating and a price target of $61.00.

The analyst comments "Veracyte specializes in improving diagnosis and prognosis accuracy for Thyroid, Lung and Breast cancers by helping to inform when costly interventions such as surgeries can be avoided. With its recent acquisition of nCounter from Nanostring and a breadth of products in their pipeline, we believe Veracyte is well positioned for accelerated growth as they continue to expand their testing menu and gain broader adoption from customers."

For an analyst ratings summary and ratings history on Veracyte, Inc click here. For more ratings news on Veracyte, Inc click here.

Shares of Veracyte, Inc closed at $52.57 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Definitive Agreement